AromaFlora aims to grow the finest quality Fairtrade fragranced roses in Kenya and deliver them to your door here in Europe. AromaFloras strong focus on corporate social responsibility and our use of renewable energy sources and environmentally friendly techniques will help establish the AromaFlora brand and enable the production of Fairtrade approved roses targeted at the 340 million European rose market. Revenues generated from these roses will fund the in-house development of AromaFloras fragrance technology, leading to the generation of our value added roses. AromaFloras Fast Flower Model will further increase profit margins by excising the middle men.

A fabless semiconductor company, BOPPHY Technologies will design, develop and market innovative digital integrated circuits for broadband communications over the existing electrical infrastructure. Broadband over powerlines (BOP) gives customers high-speed internet access through the existing power grid network and enables utility companies to add data services to their offering. By exploiting state of the art modulation and coding techniques, our implementation of the physical layer (PHY) will ease competition against other broadband services by increasing current data rates of cable and DSL by up to a factor of 10.

Recent work at the University of Coventry has led to the discovery of a new supercapacitive material capable of storing 10 times more electrical energy than competing materials. Consequently, the patent-protected Cam-Cap supercapacitor is able to combine the large energy storage capacity of batteries with the rapid power delivery capabilities of capacitors to meet new customer needs that cannot be satisfied using other existing energy storage materials. The advantages of the Cam-Cap supercapacitors are particularly apparent in the rapidly expanding high performance energy storage markets associated with environmentally friendly alternatives in the transport and power generation industries.

Cambfix is a business prospect that provides innovative, high quality medical devices for use in orthopaedic and trauma surgery. Every year there are 1.5 million ankle and wrist fractures, which costs the healthcare industry $3 billion. Over one third of these cases develop a complication during treatment. Cambfixs first generation products have a patentable technology that addresses these complications in their entirety and can thereby save the healthcare industry $800 million in ankle and wrist fractures alone. The product pipeline also includes fixators for other fractured bones, soft tissue corrections, paediatric, veterinary and military use. Our products are non-invasive, offer a superior mode of treatment and will reduce patient morbidity by decreasing complications to less than 1%.

Coventry Performance Solutions (CPS) has identified a current market opportunity to undertake performance improvement using advanced control technology in the pulp & paper and batch fermentation industries. In the past seven years advanced control has matured in academia and can now handle the fast, unstable and nonlinear dynamics seen in these industries. The close partnership with the University of Coventry Control Group, who have pioneered many of these advancements, as well as the 35 years industrial experience of their Chief Executive Officer, makes CPS ideally positioned to bring the most recent developments to new process sectors.

c2i aims to become a world-leading carbon fibre composites design, engineering and production company. It will enjoy high growth and margins due to its low cost Slovak manufacturing base and low cost production processes yielding 30-50% total cost savings in a $42 billion industry. c2i will design and manufacture its own products, the first being a revolutionary carbon fibre wheelchair. c2i will also pursue subcontracting for the aerospace, automotive, boat and leisure industry. c2is first contract is a revolutionary prefabricated palm tree house aimed at 5 star hotels and wealthy families gardens.

There are 130,000 patients worldwide who undergo peritoneal kidney dialysis using 200 million consumable fluid packs annually. Users under the current system have a 1 in 200 chance of getting a serious infection every year during the connection process. Due to the poor design of current systems, patients experience gatal infections, irritating rashes, general discomfort and difficulty in operating the critical equipment. ConnectEases technology dramatically reduces the rate of infection and training time required, whilst addressing the issues of patient comfort and ergonomics. Expected revenues are 500 million by 2010 and 1.3 billion by 2015.

EnvAls novel technology is capable of recycling 100% of the waste obtained from post consumer drink cartons (i.e. Tetra Paks). The process recovers clean aluminium that can be sold to the aluminium industry and generates oils and gases suitable for heat or electricity production. EnvAl will contribute to the sustainable development of society by generating profit and by reducing the amount of materials that are currently being landfilled. EnvAl is seeking the partnership of an early stage investor who will provide financial backing to finish building the first demonstration equipment, and then remain with the company to realise its full potential.

Linguit is a human language technology company whose first product is Nuggets, an SMS based internet search engine. Nuggets wallows mobile phone subscribers to text their questions to a service number and receive answers within seconds. The market for premium information services is expected to grow to $100 million by 2006 in the UK alone, a fraction of the billion dollar information services market. Other companies provide SMS based question and answer services but use people to search the internet, whereas Nuggets is automated. Nuggets is much faster than these competing services and costs much less to provide.

Depression and anxiety are poorly diagnosed in primary care. There is a clear need for a reliable, convenient diagnostic system for use in this setting. MoodLab combines cutting-edge technology with statistical models in a hand-held device to provide a reliable, office-based, diagnostic system for depression and anxiety for use I nprimary and specialist care.

SimuGen is a gene profiling company applying techniques from computational biology and wet lab research to provide cheaper ethical healthcare. SimuGen creates value by bringing to market an analytically powerful solution to ascribe the toxicity of compounds, thereby extensively reducing downstream animal testing. This transcribes into vastly reduced costs and timelines in preclinical testing. Protection of our assets will be mediated through our proprietary databank of gene expression profiles and will be reinforced by future patents on our gene combinations and algorithms. As a platform technology our solution is easily transferable to a range of other markets, including personal care.